tirzepatide hypertension and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial Patients who took the anti-obesity

The FDA has formally approved Wegovy and Mounjaro for the following uses: Wegovy: Long-term weight management, along with diet and exercise, in: adults and children ages 12 years and older who have obesity adults who are overweight and have a weight-related health condition, such as high cholesterol, high blood pressure, or diabetes To decrease the risk of serious cardiovascular problems in adults who have cardiovascular disease and are overweight or have obesity Long-term treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis in adults Mounjaro: Long-term management of blood sugar levels, along with diet and exercise, in adults with type 2 diabetes Wegovy and Mounjaro are both prescribed for weight loss and long-term weight management

doi: 10.1016/S0140-6736(15)00803-X 75 NewsomePNBuchholtzKCusiKLinderMOkanoueTRatziuVet al

Tags: Diabetes, GLP-1 Therapies, Heart Disease, Weight Loss, CINEMA

CJC-1295 + Ipamorelin is a peptide blend widely researched for its role in supporting growth-hormone signaling and recovery-focused wellness routines